Company:  ALLOGENE THERAPEUTICS, IN ... (ALLO)
Form Type:  10-Q
Filing Date:  11/5/2019 
CIK:  0001737287 
Address:  210 EAST GRAND AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 457-2700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$17.25  
Change: 
0.68 (4.10%)  
Trade Time: 
Aug 12  
Market Cap: 
$2.48B
Trade ALLO now with 

© 2022  
Description of Business
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy, has emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers.
Register and access this filing in:     
  FORM 10-Q
    PART I: FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        BALANCE SHEET
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 4. Controls and Procedures.
    PART II-OTHER INFORMATION
      Item 1. Legal Proceedings
        NAME AND TITLE
      Item 6. Exhibits.
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,